We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Stem Cell Defects May Cause Breast Cancer

By Biotechdaily staff writers
Posted on 28 Oct 2005
The onset of breast cancer may be caused by defects in somatic adult stem cell niches that exist long before a tumor develops, according to researchers at the Lombardi Comprehensive Cancer Center of Georgetown University (Washington, DC, USA).

The research built on prior findings that demonstrated the existence of five different types of cells in normal breast cancer tissue. More...
Two are stem cell-like and give rise to the other three. For the current study, all cell types were identified at low magnification, allowing more cells to be counted. Not only did each cell population have a different size in normal breast tissue but the cells are arranged in particular relationships to each other. These form repeating units called stem cell niches and provide microenvironments that house the adult stem cells and their daughter cells.

In mice that expressed excess amounts of either of the cancer-producing proteins, the size of the cell populations changed in relation to each other. The order of the cell arrangements was disrupted in the stem cell niches of mice with breast cancer, showing that each cell population may play a different role in the development of breast cancer and that the environment in which a cell grows can influence its chance of becoming cancerous.

"The results also show how complicated cancer is as a disease,” said lead author Gloria Chepko, Ph.D., a postdoctoral fellow at the Lombardi Comprehensive Cancer Center. "Although it's not something that will be solved easily or quickly, our study reveals important information on the genesis of breast cancer in the body.” The findings were reported in the October 2005 issue of Tissue and Cell.




Related Links:
Lombardi Comprehensive Cancer Center

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.